| Endovascular recanalization of basilar artery occlusion 80 days after symptom onset. | |
| | |
MedLine Citation:
|
PMID: 17322092 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND PURPOSE: Acute basilar artery occlusion portends high risk of stroke and death. Thrombolysis or endovascular therapy has been limited to patients who present within hours of symptom onset. Without recanalization, acute basilar artery occlusion almost always results in death or severe disability. SUMMARY OF CASE: We report a case of basilar artery occlusion and successful endovascular recanalization 80 days after symptom onset. CONCLUSIONS: Endovascular therapy can be feasible and safe for symptomatic basilar artery occlusion at chronic stage. |
| | |
Authors:
|
Wengui Yu; Varoujan Kostanian; Mark Fisher |
Publication Detail:
|
Type: Case Reports; Journal Article Date: 2007-02-22 |
Journal Detail:
|
Title: Stroke; a journal of cerebral circulation Volume: 38 ISSN: 1524-4628 ISO Abbreviation: Stroke Publication Date: 2007 Apr |
Date Detail:
|
Created Date: 2007-03-28 Completed Date: 2007-05-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0235266 Medline TA: Stroke Country: United States |
Other Details:
|
Languages: eng Pagination: 1387-9 Citation Subset: IM |
Affiliation:
|
Department of Neurology, University of California, Irvine, CA, USA. wyu@yahoo.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antibodies, Monoclonal
/
therapeutic use Basilar Artery / drug effects*, physiopathology, surgery* Cerebral Angiography Chronic Disease Fibrinolytic Agents / therapeutic use Headache / etiology Humans Immunoglobulin Fab Fragments / therapeutic use Magnetic Resonance Imaging Male Middle Aged Paresis / etiology Platelet Aggregation Inhibitors / therapeutic use Stents / standards* Thrombolytic Therapy / methods* Tissue Plasminogen Activator / therapeutic use Tomography, X-Ray Computed Treatment Outcome Vascular Surgical Procedures / instrumentation, methods* Vertebrobasilar Insufficiency / pathology, physiopathology, therapy* Vision, Low / etiology |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Fibrinolytic Agents; 0/Immunoglobulin Fab Fragments; 0/Platelet Aggregation Inhibitors; 143653-53-6/abciximab; EC 3.4.21.68/Tissue Plasminogen Activator |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Altered retrobulbar hemodynamics in patients who have transient monocular blindness without carotid ...
Next Document: Assessment of functional outcome in a national quality register for acute stroke: can simple self-re...